H.C. Wainwright views the results from ardiol Therapeutics’ Phase II ARCHER trial of CardiolRx in acute myocarditis as “very supportive” of future development. The safety “was very clean,” further validating the broader CardiolRx and, by extension, CRD-38 development programs, the analyst tells investors in a research note. H.C. Wainwright believes this morning’s data supports its positive view on Cardiol shares and enhances CardiolRx’s attractiveness to a strategic partner. It reiterates a Buy rating on the shares with a $9 price target The company’s current market cap of $112M ascribes no credit for a positive readout in ARCHER, and today’s release “is a positive,” says H.C. Wainwright.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDL:
- Cardiol Therapeutics announces Phase II ARCHER results in myocarditis
- Cardiol Therapeutics Reports Promising Phase II Trial Results for CardiolRx™ in Acute Myocarditis
- Positive Outlook for Cardiol Therapeutics Amid ARCHER Trial Progress and Market Potential
- Cardiol Therapeutics Achieves Database Lock in ARCHER Trial for Acute Myocarditis